US targets Chinese biotech investment, but licensing deals remain exempt
The US government is seeking to curb American investment in Chinese firms involved in advanced drug development after adding the…
23 Oct 2026
Gilead spends $1.28bn on PepStar’s potential Icotyde rival
Gilead Sciences has inked a billion-dollar deal with Shanghai-based PepStar therapeutics to secure the global rights to an oral IL-23 receptor inhibitor, which the company hopes will rival Johnson &…
23 Oct 2026
Boehringer and Microsoft collaborate to explore AI in clinical research
Boehringer Ingelheim and Microsoft have entered a strategic collaboration to examine the use of AI in clinical research, beginning with studies in lung health. The partnership focuses on evaluating digital…
23 Oct 2026
Celltrion and Kaigene sign $580m licence deal for KG013
South Korean biopharmaceutical company Celltrion has acquired exclusive global development and commercialisation rights to Kaigene's investigational monoclonal antibody, KG013, in a deal worth up to Won769bn ($580m). The financial package…
22 Oct 2026
Roche’s pharma sales grow 7% but pipeline trimmed down
Roche posted a healthy 7% growth for its pharmaceutical division in the first nine months of 2026, though the drugmaker discontinued several clinical programmes amid asset prioritisation. Sales for Roche’s…
22 Oct 2026
AstraZeneca bags another US indication for Ultomiris with IgAN approval
AstraZeneca has notched another indication to the belt of its rare disease therapy Ultomiris (ravulizumab) through an accelerated US approval in primary immunoglobulin A nephropathy (IgAN), a type of chronic…
22 Oct 2026
Astellas and AI Proteins sign miniprotein therapeutics deal
AI Proteins has signed a research collaboration and licence agreement with Astellas Pharma’s affiliate Astellas Innovation Management for discovering and developing miniprotein therapeutics. Under the deal, AI Proteins is set…